Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Acute Lymphoblastic Leukemia and Lymphoma Subjects

NCT03156101 is registered in ClinicalTrials.gov with Shenzhen BinDeBio Ltd. as lead sponsor.

NCT NCT03156101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03156101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Acute Lymphoblastic Leukemia and Lymphoma Subjects
Lead sponsor
Shenzhen BinDeBio Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 2, 2017
Completion date
December 30, 2021
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell acute lymphoblastic leukemia, relapsed b-cell acute lymphoblastic leukemia, relapsed／refractory b-cell lymphoma